Page 84 - أبحاث كلية الصيدلة 2016-2020

2019 Publications

Pharmacoepidemiol Drug Saf.
2019;28(S2):5-586

The cost of hospitalization and length of stay due to hypoglycemia in patients with
diabetes mellitus: A cross‐sectional study

Abdallah Y. Naser; Sinaa Alaqeel; Hassan Alwafi
Background: hypoglycemia in patients with diabetes mellitus is a frequent and costly
adverse drug event. There have been no studies in the Middle East countries that
estimate the hospitalization cost and length of stay due to hypoglycemia in patients with
DM.
Objectives: to estimate hospitalization cost and length of stay due to hypoglycemia, and
to identify determinants of variation in hospitalization cost and length of stay among
patients with diabetes mellitus.
Methods: a cross‐sectional study was conducted in Jordan using inpatients records of
two private hospitals for patients with diabetes mellitus, who have been hospitalized
due to hypoglycaemia between January 2009 and May 2017. All hospitalization costs
were inflated to costs in 2017. Hospitalization cost was estimated from patients
perspective in Jordanian dinars (JOD). Multiple linear regression analysis was used to
identify predictors of hypoglycemia hospitalization cost and length of stay.
Results: a total of 126 patients with diabetes mellitus were hospitalized due to
hypoglycemia. The mean patients age was 64.2 (SD = 19.6) years old, of which half
were male. The median length of hospital stay was two days (IQR = 2 days). The
median cost of hospitalization for hypoglycemia was 163.2 JOD ($230.1) (IQR = 216.3
JOD, $305.0). Patients who had a family history of diabetes mellitus had higher
hospitalization cost and longer length of stay (0.306 and 0.275, p < 0.05). Male patients
and patients who were without smoking history had longer length of stay (0.394 and
0.456, p < 0.01).
Conclusions: hospitalization due to hypoglycaemia among patients with diabetes
mellitus represents a substantial economic burden within hospital settings. Healthcare
professionals should give more attention to this adverse drug event to decrease the
burden of its associated cost

https://onlinelibrary.wiley.com/doi/full/10.1002/pds.4864

69